About us |
Key research questions can only be answered through multidisciplinary and networking approaches. Until the establishment of ReSViNET there was no international, integrated, multidisciplinary and translational research approach focused on RSV infections.
With the introduction and scaling up of vaccines against Streptococcus pneumoniae and Haemophilus influenzae type B in developing countries, the relative importance of RSV as an etiology of pediatric pneumonia becomes all the more important. Therefore, there has been an unprecedented interest in RSV research with an increasing number of studies underway and more to appear with the development of new diagnostics as well as preventive and therapeutic intervention.
In this setting, ReSViNET was founded in Utrecht, The Netherlands on January 14th, 2014 by 9 clinician scientists and Julius Clinical, an Academic Research Organization,as a fully independent research network with the mission to decrease the global burden of RSV infection. The founding members, who share many values professionally, had already been connected through research, education or other network activities.
ReSViNET is stimulating and performing research aiming to understand the burden of RSV infection, to advocate for better care for patients with RSV infection, to provide education related to RSV infection and to provide effective partnerships with relevant stakeholders.
ReSViNET is a network that will increase the knowledge for trial design and provide partnership in performing clinical trials, in close collaboration with Julius Clinical as a significant partner offering trial support and expertise.
With the introduction and scaling up of vaccines against Streptococcus pneumoniae and Haemophilus influenzae type B in developing countries, the relative importance of RSV as an etiology of pediatric pneumonia becomes all the more important. Therefore, there has been an unprecedented interest in RSV research with an increasing number of studies underway and more to appear with the development of new diagnostics as well as preventive and therapeutic intervention.
In this setting, ReSViNET was founded in Utrecht, The Netherlands on January 14th, 2014 by 9 clinician scientists and Julius Clinical, an Academic Research Organization,as a fully independent research network with the mission to decrease the global burden of RSV infection. The founding members, who share many values professionally, had already been connected through research, education or other network activities.
ReSViNET is stimulating and performing research aiming to understand the burden of RSV infection, to advocate for better care for patients with RSV infection, to provide education related to RSV infection and to provide effective partnerships with relevant stakeholders.
ReSViNET is a network that will increase the knowledge for trial design and provide partnership in performing clinical trials, in close collaboration with Julius Clinical as a significant partner offering trial support and expertise.
Mission & Vision
Our vision is to combine expertise and leadership in order to decrease ...
|
The Resvinet board
Our boards consists of acclaimed RSV experts
|
Our Partners
Although ReSViNET was founded by European researchers, the network aims to collaborate with stakeholders outside of Europe, such as....
|
ReSVInet global reach
An overview of our global reach
|
The new members of the board and a number of juniors.